Lykos accepts FDA’s view that reviving rejected MDMA therapy’s fortunes requires fresh phase 3 trial
Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...
In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...
The FDA has indicated a path forward for the first psychedelic-assisted therapy, its developer which failed to win approval ...
As Massachusetts prepares to vote on a measure that would legalize psilocybin and other plant-based psychedelic substances, ...
The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...
Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...
Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.
The latest version of ICER’s evidence report (PDF) on Lykos’ MDMA-assisted psychotherapy for PTSD points to “functional unblinding in the clinical trials and additional concerns around trial ...
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback